C3J Therapeutics, Inc. (C3J) a private clinical stage biotechnology company focused on the development of novel targeted antimicrobials based on bacteriophage, announced that the United States Patent and Trademark Office (USPTO) has issued patent No. […]
Danish bioscience company, Chr. Hansen, joins forces with Lonza AG to pioneer the emerging market for live biotherapeutic products Chr. Hansen Holding A/S, a leading global bioscience company, and Lonza AG, a leading pharma contract […]
Holobiome, a biotechnology company developing microbiome therapeutics that target the gut-brain-axis, announces a research collaboration with Johnson & Johnson Consumer Inc. focused on developing proprietary bacterial consortia to treat digestive disorders. Johnson & Johnson Innovation […]
Dutch biotechnology company Micreos announced it has secured €30 million in funding to accelerate the development of its endolysin technology, set to replace antibiotics. Proceeds are earmarked for the clinical development program of its endolysin […]
Viome, a company transforming health through personalized nutrition based on individual biology, announced it will collaborate with precision health leader, Helomics, to study the link between the gut microbiome and ovarian cancer. The teams will […]
It may be possible to lower the high risk of preterm birth among African American women with certain immune and bacterial factors in the microbiome of the cervix and vagina that appear to modulate this […]
Results from a clinical trial performed by Taverniti and colleagues from the University of Milan (IT) suggest that ingesting higher doses of multispecies probiotic formulations may permit higher, earlier and longer recovery of probiotics in […]
The Microbiome Therapeutics Innovation Group (MTIG) announced the publication of its Position Statement on Fecal Microbiota Transplantation (FMT) treatment. The statement supports the FDA Draft Guidance providing for patient access to FMT treatment through clinical […]
ENTEROME SA, a clinical-stage biopharmaceutical company leveraging its unique knowledge of the key functional and molecular interactions between the gut microbiome and the human body to develop targeted therapeutics, has entered into a research and […]
Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced a three-year research collaboration with AstraZeneca. The collaboration will focus on advancing mechanistic understanding of the microbiome in augmenting the efficacy of cancer immunotherapy, including potential synergy with […]
SNIPR BIOME, a leading CRISPR and microbiome private biotech company incorporated in Copenhagen, Denmark, today announced a $50 million series A financing led by existing investor Lundbeckfonden Emerge (Copenhagen) and LSP (Amsterdam), together with North-East […]